Heron Therapeutics (NASDAQ:HRTX) Bolsa

Heron Therapeutics

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Heron Therapeutics Inc

<h3>Gainers</h3>
<ul>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) shares rose 225.5% to $5.24 during Wednesday's pre-market session. The company's market cap stands at $14.2 million. </li>
<li>Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) stock rose 66.94% to $1.97. The market value of their outstanding shares is at $299.6 million. </li>
<li>Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) stock moved upwards by 62.36% to $18.12. The market value of their outstanding shares is at $612.6 million. </li>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) stock increased by 32.97% to $0.48. The market value of their outstanding shares is at $24.5 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock rose 26.42% to $17.7. The company's market cap stands at $38.4 million. </li>
<li>Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) shares increased by 21.0% to $0.2. The company's market cap stands at $7.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) stock decreased by 74.7% to $0.7 during Wednesday's pre-market session. The market value of their outstanding shares is at $21.1 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) stock fell 12.55% to $20.99. The company's market cap stands at $30.6 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares fell 11.73% to $0.48. The company's market cap stands at $4.2 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock fell 9.26% to $0.36. The market value of their outstanding shares is at $6.0 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares fell 9.04% to $0.74. The company's market cap stands at $3.7 million. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares fell 8.7% to $0.6. The company's market cap stands at $17.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BMRA

CCRN

CYCN

CYTH

ERNA

FBRX

HRTX

QNRX

RLMD

VIRX

WINT

XCUR

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

WIIM

Heron Therapeutics shares are trading higher. Needham reiterated a Buy rating on the stock.

Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) with a Buy and maintains $4 price target.

News

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Heron Therapeutics, Maintains $4 Price Target

Shares of Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) rose sharply in today's pre-market trading after the company reported better-than-expected third-quarter financial results and issued fourth-quarter <a href="https://www.benzinga.com/news/earnings/24/12/42302752/marvell-technology-stock-climbs-after-better-than-expected-q3-results-strong-q4-guidance">guidance above estimates</a>.
Marvell Technology reported quarterly earnings of 43 cents per share, which beat the analyst consensus estimate of 41 cents. Quarterly revenue came in at $1.52 billion, which beat the consensus estimate of $1.46 billion and is an increase over sales of $1.42 billion from the same period last year.
Marvell Technology shares jumped 12.6% to $108.00 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>CN Energy Group. Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>) gained 151.8% to $0.7953 in pre-market trading. CN Energy received extension from Nasdaq to meet minimum bid price requirement until May 2025.</li>
<li>Fusion Fuel Green PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) rose 81.5% to $0.5770 in pre-market trading after dipping 6% on Tuesday.</li>
<li>Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) gained 80.5% to $2.13 in pre-market trading. Heron Therapeutics said US District Court ruled in its favor in patent litigation against Fresenius Kabi with respect to CINVANTI Injectable Emulsion.</li>
<li>Viracta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) gained 50.2% to $0.2445 in pre-market trading.</li>
<li>Tantech Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TANH#NASDAQ">TANH</a>) gained 22.8% to $0.2015 in pre-market trading after gaining 12% on Tuesday.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) gained 21.4% to $17.00 in pre-market trading after tumbling 37% on Tuesday.</li>
<li>NFT Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MI#NYSE">MI</a>) gained 23.3% to $5.350 in pre-market trading after gaining 8% on Tuesday.</li>
<li>Pure Storage, Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) rose 22.3% to $65.50 in pre-market trading after the company reported better-than-expected third-quarter financial results and issued fourth-quarter guidance above estimates.</li>
<li>Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) gained 13% to $374.38 in pre-market trading. The company posted downbeat earnings for its third quarter, while sales topped estimates. The company also said it sees full-year 2025 revenue of $37.8 billion to $38 billion and full-year adjusted earnings to be between $9.98 and $10.03 per share.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Oriental Rise Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIS#NASDAQ">ORIS</a>) shares tumbled 44.4% to $6.65 in pre-market trading after jumping 82% on Tuesday.</li>
<li>Bolt Projects Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSLK#NASDAQ">BSLK</a>) declined 22.6% to $0.5031 in pre-market trading after declining 8% on Tuesday. The company recently announced a private placement of 1.06 million shares for $360K in gross proceeds.</li>
<li>Ensysce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares fell 17.3% to $0.4550 in pre-market trading as the company announced a 1-for-15 reverse stock split.</li>
<li>Cheetah Net Supply Chain Service Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) fell 16.7% to $4.07 in pre-market trading. Cheetah Net Supply Chain Service shares jumped 160% on Tuesday after the company announced the acquisition of TW &amp; EW Services in a cash and stock mixed transaction valued at $1 million.</li>
<li>ZJK Industrial Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) shares fell 13.4% to $14.95 in pre-market trading. ZJK Industrial shares jumped 172% on Tuesday after the company announced it received a request to produce samples for one of NVIDIA&#8217;s upcoming liquid cooling manifold projects.</li>
<li>Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) fell 12.7% to $12.36 in pre-market trading. Intuitive Machines priced its upsized $110.0 million offering of shares of its Class A common stock and concurrent private placement.</li>
<li>ESGL Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESGL#NASDAQ">ESGL</a>) fell 11.6% to $1.30 in pre-market trading after declining around 6% on Tuesday.</li>
<li>Volato Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NASDAQ">SOAR</a>) dipped 10.1% to $0.3290 in pre-market trading. Volato Group shares jumped 65% on Tuesday after the company unveiled a patent-pending Bitcoin mining technology.</li>
<li>Gaotu Techedu Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOTU#NYSE">GOTU</a>) shares dipped 9.7% to $2.69 in pre-market trading following third-quarter results.</li>
<li>Crescent Energy Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NASDAQ">CRGY</a>) fell 5.4% to $14.32 in today's pre-market trading. Crescent Energy Company priced its upsized public offering of 21.5 million Class A common shares at $14/share.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42293707/jim-cramer-prefers-this-delivery-giant-over-ups">Jim Cramer Prefers FedEx Over This Delivery Giant That &#8216;Screwed Up A Lot Of Holiday Seasons&#8217;</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

BSLK

CNEY

CRGY

CTNT

ENSC

ESGL

GSX Techedu Inc. American Depositary Shares

GOTU

HTOO

LUNR

MRVL

ORIS

PSTG

SOAR

TANH

Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

The district court decision concludes the litigation initiated in July 2022 in response to Fresenius' submission of an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval of a generic version of CINVANTI.&nbsp;
As a result of the decision, Heron will seek an order from the Court prohibiting Fresenius from launching its generic CINVANTI until after the expiration of the patents in 2035. This decision is subject to appeal.

Legal

Heron Therapeutics Says US District Court Ruled In Its Favor In Patent Litigation Against Fresenius Kabi With Respect To CINVANTI Injectable Emulsion

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler boosted the price target for Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) from $67 to $94. Piper Sandler analyst Clarke Jeffries maintained a Neutral rating. Shopify shares closed at $108.92 on Tuesday. <a href="https://www.benzinga.com/quote/SHOP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham cut the price target for Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) from $5 to $4. Needham analyst Serge Belanger maintained a Buy rating. Heron Therapeutics shares closed at $1.28 on Tuesday. <a href="https://www.benzinga.com/quote/HRTX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs raised Live Nation Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) price target from $132 to $148. Goldman Sachs analyst Stephen Laszczyk maintained a Buy rating. Live Nation shares settled at $129.67 on Tuesday. <a href="https://www.benzinga.com/quote/LYV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised Shift4 Payments, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) price target from $93 to $120. Piper Sandler analyst Clarke Jeffries maintained an Overweight rating. Shift4 Payments shares closed at $99.12 on Tuesday. <a href="https://www.benzinga.com/quote/FOUR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Phillip Securities boosted Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) price target from $420 to $485. Phillip Securities analyst Jonathan Wolleben downgraded the stock from Buy to Accumulate. Spotify shares closed at $419.39 on Tuesday. <a href="https://www.benzinga.com/quote/SPOT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Redburn Atlantic cut Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) price target from $84 to $77. Redburn Atlantic analyst Edward Lewis downgraded the stock from Neutral to Sell. Starbucks shares closed at $98.80 on Tuesday. <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. increased the price target for MAG Silver Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAG#NYSE">MAG</a>) from $18 to $20. HC Wainwright &amp; Co. analyst Heiko Ihle maintained a Buy rating. MAG Silver shares settled at $15.22 on Tuesday. <a href="https://www.benzinga.com/quote/MAG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group boosted Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) price target from $321 to $365. Evercore ISI Group analyst David Raso downgraded the stock from In-Line to Underperform. Caterpillar shares closed at $393.01 on Tuesday. <a href="https://www.benzinga.com/quote/CAT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird raised the price target for Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) from $120 to $160. Baird analyst Catherine Ramsey maintained an Outperform rating. Natera shares closed at $135.12 on Tuesday. <a href="https://www.benzinga.com/quote/NTRA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham increased Dayforce Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) price target from $82 to $95. Needham analyst Scott Berg maintained a Buy rating. Dayforce shares closed at $78.96 on Tuesday. <a href="https://www.benzinga.com/quote/DAY/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41929909/dow-sp-decline-ahead-of-key-inflation-data-tesla-trump-media-slides-fear-index-remains-in-greed-zone">Dow, S&amp;P Decline Ahead Of Key Inflation Data, Tesla, Trump Media Slides: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

FOUR

NTRA

SBUX

SHOP

SPOT

Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesday

Needham analyst Serge Belanger maintains Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) with a Buy and lowers the price target from $5 to $4.

Needham Maintains Buy on Heron Therapeutics, Lowers Price Target to $4

<h3>Gainers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock rose 61.6% to $0.21 during Tuesday's pre-market session. The company's market cap stands at $2.5 million. As per the news, the Q3 earnings report came out today. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares increased by 46.12% to $0.29. The market value of their outstanding shares is at $43.0 million. </li>
<li>Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) shares increased by 28.75% to $6.85. The market value of their outstanding shares is at $255.3 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLDP#NASDAQ">CCLDP</a>) shares rose 28.17% to $15.97. </li>
<li>Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares rose 27.56% to $2.08. The company's market cap stands at $426.1 million. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) shares moved upwards by 22.6% to $3.2. The market value of their outstanding shares is at $51.8 million. As per the press release, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) stock decreased by 40.2% to $1.1 during Tuesday's pre-market session. The market value of their outstanding shares is at $166.8 million. As per the press release, Q3 earnings came out today. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) stock decreased by 31.36% to $49.1. The company's market cap stands at $728.0 million. </li>
<li>Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) shares declined by 27.28% to $0.8. The market value of their outstanding shares is at $24.2 million. The company's, Q3 earnings came out today. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares decreased by 25.81% to $3.45. The market value of their outstanding shares is at $107.0 million. The company's, Q3 earnings came out today. </li>
<li>Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) stock fell 25.3% to $16.27. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares declined by 18.4% to $0.82. The market value of their outstanding shares is at $116.1 million. As per the press release, Q3 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CCLD

CCLDP

CERO

LGMK

NGNE

NVRO

RMTI

SNDX

STIM

TSHA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Heron Therapeutics shares are trading lower after the company reported worse-than-expected Q3 sales results and narrowed its FY24 product revenue guidance.

Guidance

Heron Therapeutics Narrows FY24 Guidance For Product Revenues, Net, Adjusted Operating Expenses, And Adjusted EBITDA

Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. The company reported quarterly sales of $32.80 million which missed the analyst consensus estimate of $36.93 million by 11.19 percent. This is a 4.35 percent increase over sales of $31.43 million the same period last year.

Earnings

Earnings Misses

Heron Therapeutics Q3 2024 GAAP EPS $(0.03), Inline, Sales $32.80M Miss $36.93M Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Biotech

General

Heron Therapeutics Reaffirms Availability And Supply Of CINVANTI, SUSTOL and APONVIE As Alternatives During Potential Intravenous Fluids Shortage

Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) with a Buy and maintains $5 price target.

Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target

Heron Therapeutics Announces FDA Approval Of Co.'s Prior Approval Supplement Application For ZYNRELEF Vial Access Needle

Heron Therapeutics Continues To Expect FY24 Product Revenues, Net Of $138M - $158M (Est $147.855M), Narrows Guidance For Adjusted Operating Expenses, Adjusted EBITDA

Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.04) by 50 percent. The company reported quarterly sales of $36.024 million which beat the analyst consensus estimate of $35.888 million by 0.38 percent. This is a 13.42 percent increase over sales of $31.762 million the same period last year.

Earnings Beats

Heron Therapeutics Q2 2024 GAAP EPS $(0.06) Misses $(0.04) Estimate, Sales $36.024M Beat $35.888M Estimate

Heron Therapeutics Announces ZYNRELEF Included In Proposed 2025 Non-Opioid Policy For Pain Relief Under Medicare OPPS And ASC Payment Systems; Effective April 1, 2025; CMS Issued Proposed Rule Based On ZYNRELEF's Postoperative Pain Indication And Potential To Reduce Opioid Use

-The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024
SAN DIEGO, July 2, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the FDA acknowledged the receipt of the Company's Prior Approval Supplement ("PAS") application for ZYNRELEF&#xAE; (bupivacaine and meloxicam) extended-release solution VAN. The FDA has assigned a PDUFA goal date of September 23, 2024.
If approved, the introduction of the VAN will replace the current vented vial spike and has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time from up to three minutes down to between twenty and forty-five seconds. The user-friendly "container-like" design of the VAN may enhance the safe use of ZYNRELEF, increase adoption, and improve the preparation process. If approved, the VAN is expected to be available for use in the fourth quarter of this year.

Heron Therapeutics Announces The FDA Acknowledged The Receipt Of The Company's Prior Approval Supplement Application For ZYNRELEF

Small Cap

Press Releases

Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance

Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance

U.S. District Court Upholds Validity of CINVANTI® Patents

Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina

Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025

Abeona Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Heron Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL